16
Participants
Start Date
June 14, 2017
Primary Completion Date
May 7, 2019
Study Completion Date
November 19, 2019
Subcutaneous Ustekinumab
Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases, Paris
URC-CIC Paris Descartes Necker Cochin
OTHER
Assistance Publique - Hôpitaux de Paris
OTHER